Search
CanSino: It is developing mRNA vaccines for preventive use and therapeutic biological products, as well as related delivery systems.
14 hour ago /
Read about 0 minute
Author：小编
CanSino issued an announcement regarding abnormal fluctuations in stock trading, stating that it has noticed recent market attention on mRNA technology, particularly the release or planned disclosure of clinical phase data for overseas mRNA cancer vaccines. The mRNA platform is one of the company's technological layouts. The company is developing mRNA vaccines for preventive use, therapeutic biological products, and related delivery systems. In the therapeutic field, the company is advancing the research and development of mRNA vaccines for indications such as glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as the development of InVivoCAR-related therapies, all of which are currently in the early stages.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
